A high-throughput drug screen targeted to the 5′untranslated region of Alzheimer amyloid precursor protein mRNA

Journal of Biomolecular Screening

Volumn 11, Issue 5, 2006, Pages 469-480

  Bandyopadhyay, Sanghamitra ^a   Ni, Jake ^b   Ruggiero, Amy ^b   Walshe, Karen ^c   Rogers, Mark S ^c   Chattopadhyay, Naibedya ^b   Glicksman, Marcie A ^b   Rogers, Jack T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Alzheimer disease; APP mRNA 5 UTR; Drugs; HTS; Inhibitors; Luciferase

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; DEFEROXAMINE; GREEN FLUORESCENT PROTEIN; LUCIFERASE; MESSENGER RNA; PRION PROTEIN;

5' UNTRANSLATED REGION; ALZHEIMER DISEASE; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; FLUORESCENCE MICROSCOPY; GENETIC TRANSFECTION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; INTERNAL RIBOSOME ENTRY SITE; NEUROBLASTOMA CELL; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPORTER GENE; RNA STRUCTURE;

5' UNTRANSLATED REGIONS; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; BASE SEQUENCE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HUMANS; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; RNA, MESSENGER; TRANSFECTION; TRANSGENES; TUMOR CELLS, CULTURED;

EID: 33747089589     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057106287271     Document Type: Article

References (41)

1. Selkoe DJ, Schenk D: Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 2003;43:545-584.
2. Fillit HM, Refolo LM: Advancing drug discovery for Alzheimer's disease. Curr Alzheimer Res 2005;2(2):105-107.
3. Selkoe DJ: Normal and abnormal biology of the beta-amyloid precursor protein. Annu Rev Neurosci 1994;17:489-517.
4. Lichtenthaler SF, Haass C: Amyloid at the cutting edge: activation of α-secretase prevents amyloidogenesis in an Alzheimer disease mouse model. J Clin Invest 2004;113(10):1384-1387.
5. Selkoe DJ: Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001;81(2):741-766.
6. Glenner GG, Wong CW: Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984;120(3):885-890.
7. Furukawa K, Sopher BL, Rydel RE, Begley JG, Pham DG, Martin GM, et al: Increased activity-regulating and neuroprotective efficacy of α-secretase-derived secreted amyloid precursor protein conferred by C-terminal heparin-binding domain. J Neurochem 1996;67:1882-1896.
8. Lahiri DK, Ge YW, Maloney B: Characterization of the APP proximal promoter and 5′-untranslated regions: identification of cell type specific domains and implication in APP gene expression and Alzheimer's disease. FASEB J 2005;19(6):653-655.
9. Zuker M: On finding all suboptimal foldings of an RNA molecule. Science 1989;244(4900):48-52.
10. Rogers JT, Leiter LM, McPhee J, Cahill CM, Zhan SS, Potter H, et al: Translation of the Alzheimer amyloid precursor protein mRNA is up regulated by interleukin-1 through 5′-untranslated region sequences. J Biol Chem 1999;274(10):6421-6431.
11. Lahiri DK, Nall C: Promoter activity of the gene encoding the beta-amyloid precursor protein is up regulated by growth factors, phorbol esters, retinoic acid and interleukin-1. Brain Res Mol Brain Res 1995;32(2):233-240.
12. Lahiri DK, Chen D, Vivien D, Ge YW, Greig NH, Rogers JT: Role of cytokines in the gene expression of amyloid β-protein precursor: identification of a 5′-UTR-binding nuclear factor and its implications in Alzheimer's disease. J Alzheimer Dis 2003;5(2):81-90.
13. Rogers JT, Randall JD, Cahill CM, Eder PS, Huang X, Gunshin H, et al: An iron-responsive element type II in the 5′ untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem 2002;277(47):45518-45528.
14. Maloney B, Ge YW, Greig N, Lahiri DK: Presence of a "CAGA box" in the APP gene unique to amyloid plaque-forming species and absent in all APLP-1/2 genes: implications in Alzheimer's disease. FASEB J 2004;18(11):1288-1290.
15. Novae O, Guenier AS, Pelletier J: Inhibitors of protein synthesis identified by a high throughput multiplexed translation screen. Nucleic Acids Res 2004;32:902-915.
16. Werstuck G, Green MR: Controlling gene expression in living cells through small molecule-RNA interactions. Science 1998;282(5387):296-298.
17. Maurel MC, Biard B, Moulinier C, Braz D, Nugier J, Chaumas I, et al: RNA-acting antibiotics: in-vitro selection of RNA aptamers for the design of new bioactive molecules less susceptible to bacterial resistance. J Pharm Pharmacol 2002;54:1019-1031.
18. Lind KE, Du Z, Fujinaga K, Peterlin BM, James TL: Structure-based computational database screening in vitro assay, and NMR assessment of compounds that target TAR RNA. Chem Biol 2002;9:185-193.
19. Hamy F, Felder ER, Heizmann G, Lazdins J, Aboul-ela F, Varani G, et al: An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication. Proc Natl Acad Sci U S A 1997;94:3548-3553.
20. Rogers JT, Jeffrey DR, Eder PS, Huang X, Bush AI, Tanzi RE, et al: Alzheimer's disease drug discovery targeted to the APP mRNA 5′untranslated region. J Mol Neurosci 2002;19(1-2):77-82.
21. Payton S, Cahill C, Randall J, Gullans S, Rogers JT: Drug discovery targeted to the Alzheimer's APP mRNA 5′-untranslated region: the action of paroxetine and dimercaptopropanol. J Mol Neurosci 2003;20(3):267-275.
22. Morse LJ, Payton SM, Cuny GD, Rogers JT: FDA preapproved drugs targeted to the translational regulation and processing of the amyloid precursor protein. J Mol Neurosci 2004;24(1):129-136.
23. Tucker S, Ahl M, Bush A, Westaway D, Huang X, Rogers JT: Pilot study of the reducing effect on amyloidosis in vivo by three FDA pre-approved drugs via the Alzheimer's APP 5′ untranslated region. Curr Alzheimer Res 2005;2(2):249-254.
24. Kretzschmar HA, Stowring LE, Westaway D, Stubblebine WH, Prusiner SB, Dearmond SJ: Molecular cloning of a human prion protein cDNA. DNA 1986;5(4):315-324.
25. Liao YC, Lebo RV, Clawson GA, Smuckler EA: Human prion protein cDNA: molecular cloning, chromosomal mapping, and biological implications. Science 1986;233(4761):364-367.
26. Hsiao K, Baker HF, Crow TJ, Poulter M, Owen F, Terwilliger JD, et al: Linkage of a prion protein missense variant to Gerstmann-Straussler syndrome. Nature 1989;338(6213):342-345.
27. Venti A, Giordano T, Eder P, Bush AI, Lahiri DK, Greig NH, et al: The integrated role of desferrioxamine and phenserine targeted to an iron-responsive element in the APP-mRNA 5′-untranslated region. Ann N Y Acad Sci 2004;1035:34-48.
28. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ: Experimental and computational approaches to estimate solubility and permeability in compound discovery and development settings. Adv Drug Deliv Rev 2001;46(1-3):3-26.
29. Bakshi P, Liao YF, Gao J, Ni J, Stein R, Yeh L-A, et al: A high-throughput screen to identify inhibitors of amyloid β-protein precursor processing. J Biomol Screen 2005;10(1):1-12.
30. Liu Y, Lashuel HA, Choi S, Xing X, Case A, Ni J, et al: Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. Chem Biol 2003;10(9):837-846.
31. Case A, Ni J, Yeh LA, Stein RL: Development of a mechanism-based assay for tissue transglutaminase - results of a high-throughput screen and discovery of inhibitors. Anal Biochem 2005;338:237-244.
32. Ahn JS, Musacchio A, Mapelli M, Ni J, Scinto L, Stein R, et al: Development of an assay to screen for inhibitors of tau phosphorylation by cdk5. J Biomol Screen 2004;9(2):122-131.
33. Zhang JH, Chung TD, Oldenberg KR: A simple statistical parameter for use in evaluation and validation of high-throughput screening assays. J Biomol Screen 1999;4(2):67-73.
34. Lundholt BK, Scudder KM, Paliaro L: A simple technique for reducing edge effect in cell- based assays. J Biomol Screen 2003;8(5):566-570.
35. Hegde RS, Tremblay P, Groth D, DeArmond SJ, Prusiner SB, Lingappa VR: Transmissible and genetic prion disease share a common pathway of neurodegeneration. Nature 1999;402(6763):822-826.
36. Collinge J, Sidle KC, Meads J, Ironside J, Hill AF: Molecular analysis of prion strain variation and aetiology of "new variant" CJD. Nature 1996;383(66020):685-690.
37. Mahal SP, Asante EA, Antoniou M, Collinge J: Isolation and functional characterization of the promoter region of the human prion protein gene. Gene 2001;268(1-2):105-114.
38. Luck R, Steger G, Riesner D: Thermodynamic prediction of conserved secondary structure: application to the RRE element of HIV, the tRNA-like element of CMV and the mRNA of prion protein. J Mol Biol 1996;258(5):813-826.
39. Jackson GS, Murray I, Hosszu LL, Gibbs N, Waltho JP, Clarke AR, et al: Location and properties of metal-binding sites on the human prion protein. Proc Natl Acad Sci U S A 2001;98:8531-8535.
40. Purdey M: Ecosystems supporting clusters of sporadic TSEs demonstrate excesses of the radical-generating divalent cation manganese and deficiencies of antioxidant co factors Cu, Se, Fe, Zn. Does a foreign cation substitution at prion protein's Cu domain initiate TSE? Med Hypotheses 2000;54(2):278-306.
41. Dedeoglu A, Cormier K, Payton S, Tseitlin KA, Kremsky JN, Lai L, et al: Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis. Exp Gerontol 2004; 39 (11-12): 1641-1649.